Answers are grounded in this paper and cite their sources.
This review will explore the four major pillars required for design and development of an saRNA vaccine: Antigen design, vector design, non-viral delivery systems, and manufacturing (both saRNA and lipid nanoparticles (LNP)). We report on the major innovations, preclinical and clinical data reported in the last five years and will discuss future prospects.
No takes yet. Share an insight, caveat, or question.
Blakney et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: